From: DDI Webinars <DDIWebinars@fda.hhs.gov> **Subject:** 1-hr "Live" CME/AAPA/CNE/CPE/CPT/CPH Webinar on: Cannabis Products and the Potential Impact on Patients sponsored by the Division of Drug Information

Please direct your comments or questions via email to DDIWebinars@fda.hhs.gov.

FDA DRUG TOPICS CE Webinars for Health Care Professionals
FDA Drug Topics: Cannabis Products and the Potential Impact on Patients Tuesday, October 29, 2024 Time: 1:00 PM – 2:00 PM (ET)
Register
After registering, you will receive a calendar invitation with details on how to join the online ZOO meeting.

An email will be sent to all participants by the next business day with instructions on how to claim CE and a copy of the presentation slides.

Activity Outline

Description: This series of educational webinars is designed to aid physicians, physician assistants, nurse practitioners, nurses, pharmacists, pharmacy technicians, certified public health professionals, other health care professionals, and students, to provide better patient care by knowing how to find relevant FDA regulatory information that will improve drug safety. This webinar will provide insights into the landscape of the cannabis marketplace and some general information on how products are manufactured and regulated. It will discuss clinical and pharmacological considerations along with known drug-drug interactions that can impact patients. The presentation will identify common misconceptions on the use and safety of cannabis products and provide attendees with accurate

information to help prevent the spread of misinformation. We will provide attendees with a greater knowledge of ways to identify and report adverse events associated with these products to FDA, as well as suggestions on how to create a safe space to discuss patient use of these products.

References:

- FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD)
- FDA and Cannabis: Research and Drug Approval Process
- FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds
- FDA's 50 Years of Experience with Cannabis Research Helping to Support Tomorrow's Cannabis Drug Development
- What You Should Know About Using Cannabis, Including CBD, When Pregnant or Breastfeeding
- <u>5 Things to Know about Delta-8 Tetrahydrocannabinol Delta-8 THC</u>

Series Objectives:

- Explain how to utilize FDA's drug information, medication safety resources, and regulatory guidance, to improve delivery of patient care and optimize outcomes.
- Describe and inform health care providers of recent labeling changes which would impact prescribing and medication management to optimize patient care.

Learning Objectives: After completion of this activity, the participant will be able to:

- Identify cannabis products on the market and how they are different from FDA regulated drugs, as well as the various ways products are manufactured and how their quality controls differ.
- Explain the potential risks associated with cannabis use, brief review of scientific evidence, and how to initiate a discussion with patients.
- Discuss how to submit a voluntary adverse event report or consumer complaint to FDA and identify important elements that should be included to constitute a high-quality submission.

Target Audience: This activity is intended for physicians, physician assistants, nurse practitioners, nurses, pharmacists, pharmacy technicians, certified public health professionals, other health care professionals, and students.

Schedule:

1:00 pm - 2:00 pm – **FDA Drug Topics: Cannabis Products and the Potential Impact on Patients** presented by Cassandra Taylor, PhD, a Public Health Advisor at FDA within CDER's Office of the Center Director, Scott Janiczak, PharmD, MPH, BCPS, a Lieutenant Commander (LCDR) in the U.S. Public Health Service, Commissioned Corps, who serves as a Safety Evaluator at FDA within CDER's Office of Surveillance and Epidemiology's, Division of Pharmacovigilance I, and Steven Galati, MD, a Senior Medical Officer within the Controlled Substance Staff at FDA within CDER's Office of the Center Director.

Continuing Education Accreditation:

In support of improving patient care, FDA Center for Drug Evaluation and Research is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),

and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.

CME

FDA Center for Drug Evaluation and Research designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)^m. Physicians and physician assistants should claim only the credit commensurate with the extent of their participation in the activity.

<u>CPE</u>

This knowledge-based activity has been assigned ACPE Universal Activity Number JA0002895-0000-24-002-L99-P, and ACPE Universal Activity Number JA0002895-0000-24-002-L99-T for 1.00 contact hour(s).


CNE

FDA Center for Drug Evaluation and Research designates this activity for 1.00 contact hour(s).

AAPA

This activity is designated for 1.00 AAPA Category 1 CME credits. FDA Center for Drug Evaluation and Research has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. PAs should only claim credit commensurate with the extent of their participation.





JOINTLY ACCREDITED PROVIDER

INTERPROFESSIONAL CONTIN



<u>CPH</u>

Up to 1.00 CPH Recertification Credits may be earned at this event.

Requirements for receiving CE Credit:

All learners claiming credit must attest to their attendance and complete all required activity evaluations in the FDA CE Portal (ceportal.fda.gov) within 14 days after this activity ends. Upon completion, learners may view or print their statement of credit.

For those of you who are pharmacists or pharmacy technicians: The FDA CE Team will report your credit to the National Association of Boards of Pharmacy—otherwise known as "NABP"—provided you add your NABP ID and date of birth to your profile in the FDA CE Portal. The only official Statement of Credit is the one you pull from CPE Monitor. If you do not see your credit reflected on the CPE Monitor after 45 days of attestation, please contact FDACETeam@fda.hhs.gov. The CPE Monitor sets a strict 60-day limit on uploading credits.

Disclosure:

Faculty:

- Galati, Steven, MD, Medical officer, FDA/CDER/OCD/CSS nothing to disclose
- Janiczak, Scott, PharmD, Pharmacist, FDA/CDER/OSE/OPE/DP1 nothing to disclose
- Taylor, Cassandra, PhD, Public Health Advisor, FDA/CDER/OCD nothing to disclose

Planning Committee:

- Burke, Kara, PharmD, Team Leader/Pharmacist, FDA/CDER/OCOMM/DDI nothing to disclose
- Cao, Christian, MPAS, PA-C, Safety Evaluator Team Leader, FDA/CDER/OSE/DPV nothing to disclose
- DeFronzo, Kimberly, RPh, MS, MBA, Consumer Safety Officer, FDA/CDER/OCOMM/DDI nothin g to disclose
- Kapoor, Rama, MD, Medical Officer, FDA/CDER/OND/OID/DAI nothing to disclose
- Nguyen-Chu, Thanh Tam, PharmD, BCPS, Pharmacist, FDA/CDER/OCOMM/DDI nothing to disclose
- Paraoan, Dianne, MPH, RN, Associate Director for Regulatory Affairs, FDA/CDER/OMP nothing to disclose

CE Consultation and Accreditation Team:

- Littlefield, Jr, Kenneth P., Training Specialist, FDA/CDER/OEP/DLOD nothing to disclose
- Bryant, Traci, M.A.T., Lead Training Specialist, FDA/CDER/OEP/DLOD nothing to disclose
- Wood, Sara, Accreditation Program Administrator, CECAT, FDA/CDER/OEP/DLOD nothing to disclose

If you are unable to attend this webinar, please note that a recording will be uploaded to our webpage about 5-7 business days after the event has concluded. Listening to this recording will not offer CE. If interested in CE, please listen to our past webinar recordings on our website under "Home Study CE Webinars".

Registration Fees and Refunds: Registration is complimentary therefore refunds are not applicable.

Please direct your comments or questions via email to DDIWebinars@fda.hhs.gov.

To learn more about future dates and registration, please visit: <u>www.fda.gov/DDIWebinars</u>.